Abstract 16711: Outcomes of Severe Mitral Stenosis With the Revised Severity Criteria: Mitral Valve Replacement versus Percutaneous Mitral Valvuloplasty

• DOI: 10.1161/circ.148.suppl_1.16711
• Publication Date: 2023-12-19T08:08:02Z
• Authors: Dae-Young Kim; Iksung Cho; Kyu Kim; Seo-Yeon Gwak; Kyungeun Ha; Hee Jeong Lee; Kyu-Yong Ko; Chi Young Y Shim; Jong-Won Ha; William Kim; In-Jai Kim; Seonhwa Lee; Incheol Kim; KANGUN CHOI; Hojeong Kim; Jang-Won Son; Geu-Ru Hong
• Keywords: Mitral valve stenosis; Mitral valve replacement

Introduction: Mitral stenosis (MS) severity is determined by mitral valve area (MVA); the threshold for severe MS was raised from MVA of 1.0 cm 2 to 1.5 in recent guidelines. Hypothesis: This study aimed compare clinical outcomes, according percutaneous valvuloplasty (PMV) versus replacement (MVR) treatment strategy, patients with updated criteria subgroups categorized and . Methods: From Multicenter mitrAl STEnosis Rheumatic etiology (MASTER) registry 3,140 patients, we included who underwent PMV or MVR between January 2000 December 2021 except previous valvular surgery/intervention, at least moderate other dysfunction, thrombus left atrium/appendage. Moderately (MS-MS) very (VS-MS) were defined as <mva≤1.5 cm2 MVA≤1.0 , respectively. Primary outcomes a composite cardiovascular (CV) death heart failure (HF) hospitalization. Secondary primary redo-intervention. Results: Among 442 (mean 56.5±11.9 years, women 77.1%), group (n=260) older, had more comorbidities, higher echoscore, larger chambers, right ventricular systolic pressure than (n=182). During mean follow-up 6.9±5.2 years inverse probability weighted matching, did not differ, but experienced fewer secondary (p=0.010). In subgroup analysis MS-MS VS-MS differ. However, showed better (p=0.012) (Figure). Conclusions: influence CV mortality HF hospitalization both VS-MS. due increased early redo-intervention VS-MS, would be preferable option without clear evidence suitable morphology PMV.